Jesse Sanders
Family Medicine · Pacoima, CANPI 1497756555
Payments from drug & device makers
Across 585 payments — averaging $229.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$87K
- Gilead$42K
- Merck$2K
- GSK$950
- AbbVie$480
- Johnson & Johnson$409
- plus $672 from 6 others
What the payments were for
- Consulting fees$24,74018%
- Speaking & faculty fees$91,54268%
- Travel & lodging$4,7744%
- Food & beverage$12,7379%
- Education$3990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 265 | $86,939 |
| Gilead | 179 | $42,267 |
| Merck | 63 | $2,476 |
| GSK | 9 | $950 |
| AbbVie | 17 | $480 |
| Johnson & Johnson(2 entities) | 31 | $409 |
| Janssen Products, LP | 4 | $371 |
| Theratechnologies Inc. | 9 | $160 |
| Napo Pharmaceuticals Inc | 5 | $87 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Pfizer | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,192 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 187 | $583,613 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 78 | $291,866 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 78 | $267,034 |
| TivicayDolutegravir Sodium | 89 | $212,492 |
| RukobiaFostemsavir Tromethamine | 25 | $208,756 |
| TrulicityDulaglutide | 158 | $173,735 |
| PrezcobixDarunavir/Cobicistat | 56 | $156,420 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 32 | $121,979 |
| JulucaDolutegravir/Rilpivirine | 34 | $111,326 |
| DescovyEmtricitabine/Tenofov Alafenam | 52 | $105,003 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 21 | $89,320 |
| JanuviaSitagliptin Phosphate | 47 | $56,545 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $50,131 |
| Isentress HdRaltegravir Potassium | 19 | $46,791 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 12 | $42,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Rukobia, Juluca, Triumeq | $86,939 | $1,166,319349 claims |
| GileadBiktarvy, Genvoya, Descovy | $42,267 | $518,848162 claims |
| Johnson & JohnsonPrezcobix, Complera | $409 | $198,92268 claims |
| MerckJanuvia, Isentress Hd | $2,476 | $103,33566 claims |
| Janssen Products, LPSymtuza | $371 | $89,32021 claims |
| PfizerEliquis | $17 | $40,31350 claims |
| GSKArnuity Ellipta | $950 | $3,82116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Pacoima
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.